1. Home
  2. LYEL vs ORBS Comparison

LYEL vs ORBS Comparison

Compare LYEL & ORBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$13.01

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Logo Eightco Holdings Inc.

ORBS

Eightco Holdings Inc.

HOLD

Current Price

$0.78

Market Cap

337.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYEL
ORBS
Founded
2018
1966
Country
United States
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.1M
337.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LYEL
ORBS
Price
$13.01
$0.78
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$30.60
N/A
AVG Volume (30 Days)
135.4K
22.4M
Earning Date
05-13-2026
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8,712.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.49
$0.72
52 Week High
$45.00
$15.96

Technical Indicators

Market Signals
Indicator
LYEL
ORBS
Relative Strength Index (RSI) 39.11 39.74
Support Level $12.00 $0.77
Resistance Level $13.88 $1.28
Average True Range (ATR) 1.05 0.10
MACD 0.18 -0.01
Stochastic Oscillator 54.44 2.62

Price Performance

Historical Comparison
LYEL
ORBS

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

About ORBS Eightco Holdings Inc.

Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.

Share on Social Networks: